NCT04484909View on ClinicalTrials.gov

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal AdenocarcinomaStage III Pancreatic Cancer AJCC v8

Interventions

OTHER

Hafnium Oxide-containing Nanoparticles NBTXR3

Given IT

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER